AbbVie has ended its collaboration deal with Alector to develop one of two potential Alzheimer’s disease drugs. However, the relationship isn’t totally severed between the pair as they are still working to develop AL002, which is focused on targeting triggering receptors expressed on myeloid cells 2 (TREM2) also for Alzheimer’s Disease.